Leqselvi patent litigation binary outcome
The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.
high · analyst_question
Sunpharma Ltd — Q2 FY25
Sun Pharma delivered a strong Q2 FY25 with consolidated sales of INR 13,264 crore, up 10.5% YoY, driven by US specialty growth (+20.3% to $517M) and India formulation growth (+1...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
R&D spend may remain below guidance if trials delay further
Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.
medium · management_commentaryHigher selling expenses pressuring margins
Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.
medium · data_observationJapan price cuts impacting ROW revenues
Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management.
medium · management_commentary